Disclaimer: This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to your own physician before making decisions about cancer screening, testing, or treatment. TL;DR * A healthy 58-year-old gets a routine full-body scan, finds a “cancer” that would never have hurt him, and ends up with permanent incontinence from unnecessary treatment. This is more common than most people realize. * Dr. H. Gilbert Welch, a Dartmouth-trained cancer epidemiologist, spent 30 years documenting overdiagnosis — the discovery of cancers that meet the technical definition but would never have caused harm. His estimate: roughly 60% of PSA-detected prostate cancers and 25% of mammography-detected breast cancers fall into this category. * The “5-year survival rate” you hear cited as proof screening saves lives is often distorted by lead-time bias — finding a cancer earlier can make survival numbers look better without adding a single day to anyone’s life. * Not all screening is suspect. Colonoscopy, low-dose CT for high-risk smokers, and cervical cancer screening (Pap/HPV) have strong randomized-trial evidence behind them. * The piece conventional screening misses: metabolic health. A 2026 Nature Communications study using machine learning on UK biobank data linked insulin resistance to increased risk across at least 12 cancer types — independent of body weight — and standard checkups rarely test for it. * Want a personalized look at your own metabolic terrain? Book a Metabolic Audit Call — link in show notes, spots limited weekly. The Test That Didn’t Save His Life Picture a 58-year-old man. Healthy weight, active, doesn’t smoke, feels completely fine. He goes in for a routine total-body scan — the kind now available at imaging centers with no doctor’s referral required. Two hours later, a radiologist flags a small spot on his prostate. Six months, two biopsies, and one surgery later, he has a diagnosis: permanent incontinence. And the cancer itself? “Clinically insignificant.” It almost certainly would never have caused him harm. He would have lived out a full life and died of something else entirely, never knowing it was there. The test didn’t save his life. It changed it — for the worse. This scenario happens thousands of times a year, and it’s exactly what Dr. H. Gilbert Welch — a general internist, cancer epidemiologist, and senior researcher at Brigham and Women’s Hospital — spent his career warning about. His book, Should I Be Tested for Cancer?, makes a case that runs against decades of public health messaging: more testing is not automatically better testing, and early detection does not automatically mean lives saved. This article unpacks what Welch got right, where his argument leaves a gap, and what a more complete, proactive approach to cancer risk actually looks like. The Cancer Reservoir: Why Finding More Doesn’t Mean Saving More For decades, the operating assumption in medicine has been simple: catch cancer early, save the life. No asterisk, no nuance. Welch’s research complicates that. His central idea is the cancer reservoir — the observation that most people carry small clusters of abnormal cells somewhere in their bodies right now. In the prostate, thyroid, breast, or lung. Under a microscope, these cells look like cancer. But many of them will never grow, never spread, and never threaten a life. A person could carry one for thirty years and die at 87 of heart disease, never knowing it existed. The problem is that increasingly sensitive tools — full-body scans, PSA tests, low-dose CT — are very good at finding these dormant clusters. And once something is found and labeled “cancer,” the medical system is built to treat it. Welch’s numbers, drawn from randomized trial data, are striking: approximately 60% of PSA-detected prostate cancers are overdiagnosed, meaning they meet the technical definition of cancer but would never have caused symptoms or death. For mammography-detected breast cancers, the estimate is around 25% — meaning roughly one in four women treated for a screen-detected breast cancer may never have needed that treatment: the chemotherapy, the radiation, the surgery, the fear, the financial cost. This isn’t an anti-medicine argument. It’s a call for a conversation that rarely happens: here’s the case for this test, and here’s the case against it — here’s what we might find that helps you, and here’s what we might find that sets off a chain reaction you’ll spend years managing. For most patients, that conversation never occurs. The 5-Year Survival Stat Is Misleading You Five-year survival rates for cancer are often cited as evidence that screening works — and they sound like exactly that. But Welch shows why the number can be deceptive, and it comes down to lead-time bias. Here’s the mechanism. Imagine a woman whose cancer will kill her at 65, regardless of when it’s found. If screening catches it at 62, she lives three years with the diagnosis before dying at 65 — a five-year survival rate under five years. But if that same cancer isn’t found until symptoms appear at 64, she lives one year with the diagnosis and dies at 65 — a five-year survival rate of zero. Same woman. Same cancer. Same date of death. But the version of her found earlier through screening appears, statistically, to have “survived longer.” Screening didn’t add a single day to her life — it just moved up the start date of her diagnosis. It’s the equivalent of claiming a win in a race because someone moved your starting line 200 meters ahead of everyone else’s: you didn’t run faster, you just started earlier. The finish line never moved. Now layer in overdiagnosis. If 1,000 people are diagnosed with cancers that would never have hurt them, and all 1,000 are alive five years later — which they would have been regardless — the survival statistics look dramatically better without a single life actually being saved. Welch’s research shows that 5-year survival rates can climb while actual cancer death rates stay flat. More survivors on paper. Same number of people dying. None of this means medicine isn’t making genuine progress in some cancers — colon cancer being a clear example, discussed below. It does mean that 5-year survival statistics, on their own, are not proof that a screening program is saving lives. Where the Evidence for Screening Is Actually Strong It would be a mistake to leave this discussion thinking all screening is suspect. Welch himself is careful to draw a distinction, and there are tests with solid, randomized-trial evidence behind them. Colonoscopy for colorectal cancer is arguably the strongest case for screening that exists. It’s unique because it doesn’t just detect cancer — it can prevent it, by removing precancerous polyps before they ever become malignant. Colon cancer incidence and mortality have both dropped measurably in populations with high screening rates. If you’re 45 or older, or have a family history, this is worth a serious conversation with your doctor. Low-dose CT for lung cancer, in high-risk individuals specifically, showed a 15–20% reduction in lung cancer deaths in the National Lung Screening Trial — but only among heavy smokers (roughly a pack a day for 20+ years). The risk-benefit math works because the baseline risk in that population is high. Cervical cancer screening — Pap smears and HPV testing — is a genuine public health success story. Rates have dropped dramatically since routine screening began, because cervical cancer has a long, slow, detectable precancerous stage that can be caught before it turns invasive. The common thread: these screenings either catch a long, slow precancerous process, or they target a population where the risk is already high enough that the math clearly favors testing. That’s the question worth bringing to your doctor: given my specific risk factors, does the math on this test work in my favor? By contrast, the evidence is much weaker for consumer-marketed total-body scans, full-body MRI as a general “optimization” tool, universal PSA screening in all men over 50, and mammography in average-risk women in their 40s. These aren’t mandates — they’re conversations, and informed consent means understanding both sides before deciding. The Harms Nobody Talks About Healthcare marketing tends to present testing as one-sided: test early, catch it early, save your life. Welch’s research catalogs the costs that rarely make it into that pitch. False positives. A mammogram flags a shadow. It isn’t cancer — but you don’t know that yet. Six weeks of follow-up imaging, maybe a biopsy, and the stress hormones flooding your body during that stretch are a real physiological cost, even when the final answer is “you’re fine.” Unnecessary treatment. When a cancer that would never have caused harm is treated anyway — with surgery, radiation, or chemotherapy — the harm is real and the benefit is zero. The cancer label itself. Research shows that being labeled a cancer patient, even for a cancer that’s never actively treated, changes a person’s psychology, relationships, insurability, and life trajectory. Welch identifies this as a form of harm medicine rarely accounts for. Radiation exposure. Repeated CT scans carry cumulative radiation risk. A full-body scan can expose a person to the radiation equivalent of hundreds of chest X-rays — a real risk added to the body in pursuit of a cancer that may never develop. Welch’s central reframe: the question isn’t “should I get tested,” it’s “given my risk factors, my age, my family history, and my values, does the math on this specific test work in my favor?” That’s informed consent — and most people never get that conversation. The Missing Piece: Your Metabolism Is an Early Warning System Welch’s work is
